CLRB Share Price Performance
US$4.73
-53.17 (-91.83%)
Price US$4.73
Share PriceUS$4.73
CLRB Community Narratives
There are no narratives available yet.
Recent CLRB News & Updates
No updates
Cellectar Biosciences, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 14, 2025
- Earnings per share (EPS)
- -8.59
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Cellectar Biosciences, Inc. Competitors
About CLRB
- Founded
- 2002
- Employees
- 11
- CEO
- WebsiteView website
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
U.S. Market Performance
- 7 Days: 2.3%
- 3 Months: 12.9%
- 1 Year: 20.2%
- Year to Date: 8.3%
The market is up 2.3% over the last week, with the Information Technology sector leading the way, up 4.1%. The market is up 20% over the last 12 months. Earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading